Neurolytixs develops advanced biomarker discovery technology for the accurate diagnosis of concussions. The company focuses on identifying specific biological indicators that can enhance clinical assessment and improve patient outcomes in concussion management.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Concussions are challenging to diagnose accurately using current clinical assessments, which rely heavily on subjective patient reporting and lack objective biological markers. This can lead to delayed or missed diagnoses, impacting patient outcomes and recovery.
Solution
Neurolytixs is developing biomarker discovery technology to improve the accuracy of concussion diagnosis. By identifying specific biological indicators present in patients who have sustained a concussion, Neurolytixs aims to provide clinicians with objective data to enhance their assessments. This technology has the potential to improve patient outcomes through more timely and accurate diagnosis and management of concussions.
Target Audience
The primary audience includes medical professionals, such as physicians and neurologists, involved in diagnosing and treating patients with suspected concussions.
Features
- Identification of specific biological markers indicative of concussion.
- Technology designed to enhance clinical assessment of concussions.
- Focus on improving patient outcomes in concussion management.